Biotech News
Be Bio Secures $92M Series C Funding to Advance BCM Therapies
Be Bio, has successfully closed a $92 million Series C financing round. The funding was backed by new investor Nextech, along with existing investors such as ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers
20 January 2025